New treatment strategies for HIV-positive cancer patients undergoing anticancer medical
treatment: update of the literature
"Patients who receive a combination of anticancer agents (AC) and ART can achieve better
response and survival rates than patients who receive AC only. However, careful attention must
be paid to cross toxicity and possible pharmacokinetic and pharmacodynamic interactions between antiretrovirals and AC."
"Recently, long-acting antiretroviral therapy holds the promise of new options for treatment. Their conditions where long-acting schedules have proven costeffectivenesses, such as contraception and mental health, are of particular interest. Long-acting antiretroviral drugs includes: Ibalizumab and Leronlimab (monoclonal Antibody), Rilpivirine (NNRTI), cabotegavir (INSTI), Islatravir (NRTTI)94 ."
"CCR5 receptor antagonists are a group of small molecules that antagonize the CCR5 receptor. The CCR5 antagonist maraviroc is a substrate of CYP3A and ABCB1 but does not alter metabolism or transport. Leronlimab is a recent new entry in CCR5 receptor antagonist. It seems to have lower adverse events include hepatotoxicity, pyrexia, rash, and upper respiratory tract infections."
